The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Amyotrophic lateral sclerosis has been a tough area for drug research, but Eli Lilly has been spreading ... deal terms announced Tuesday, Lilly is licensing Alchemab’s ATLX-1282, an antibody ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...